Akoustis Technologies, INC 8-K filings

Aktis Oncology reported Q1 2026 financial results, highlighting progress in its radiopharmaceutical pipeline with two key drug candidates, AKY-1189 and AKY-2519, advancing in clinical trials.

Aktis Oncology has appointed industry veteran Dr. Glenn Gormley to its Board of Directors and established a new Science and Technology Committee.

Akoustis Technologies, now ATech (Parent) Resolution Corp., finalizes the sale of substantially all assets to Tune Holdings, a SpaceX subsidiary, for $30.2 million following bankruptcy proceedings.

Akoustis Technologies will be delisted from the Nasdaq Capital Market due to failure to maintain a minimum bid price and its Chapter 11 bankruptcy filing.

Akoustis Technologies has filed for Chapter 11 bankruptcy to facilitate a strategic sale of its business and assets, aiming to ensure continued operations and a sale free of prior legal encumbrances.

Akoustis Technologies has adjourned its 2024 Annual Meeting of Stockholders due to a lack of quorum and rescheduled it for January 9, 2025.

Akoustis Technologies is appealing a $38.6 million judgment in favor of Qorvo and warns it may need to seek bankruptcy protection.

Akoustis Technologies has been ordered to pay approximately $57 million in damages and fees to Qorvo, leading to significant financial uncertainty and the potential for bankruptcy.

Akoustis Technologies has adjourned its 2024 Annual Meeting of Stockholders to December 12, 2024, due to a lack of quorum.

Steven P. DenBaars has resigned from the Akoustis Technologies Board of Directors, effective immediately, with no disagreements cited.

Akoustis Technologies is facing a permanent injunction and potential bankruptcy following a legal battle with Qorvo, which resulted in a $38.6 million damages award and $19 million in fees and interest.

Akoustis Technologies has been granted continued listing on the Nasdaq Capital Market, contingent on meeting specific requirements related to minimum bid price and stockholders' equity by December 2024 and January 2025 respectively.

Akoustis Technologies has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, adding to existing delisting concerns due to low share price.

Akoustis Technologies has appointed Kamran Cheema as both a new member of the Board of Directors and as the company's permanent Chief Executive Officer, effective September 20, 2024.

Akoustis Technologies is facing significant financial uncertainty and potential bankruptcy after a court awarded Qorvo approximately $57.6 million in damages and fees.

Akoustis Technologies is facing significant financial uncertainty after a court awarded Qorvo $11.7 million in attorneys' fees, adding to a previous $38.6 million damages award.

Akoustis Technologies has received a delisting notice from Nasdaq after its share price fell below $0.10, and the company plans to appeal the decision.

Akoustis Technologies has announced the resignation of its CEO, Jeffrey B. Shealy, and several board members, alongside the appointment of an interim CEO and new directors.

Akoustis Technologies' Executive Vice President of Business Development, David M. Aichele, has resigned, with Colin Hunt stepping in as Vice President of Sales & Business Development.

J. Michael McGuire resigned from the Akoustis Technologies Board of Directors effective immediately on June 2, 2024.

Akoustis Technologies has entered into a securities purchase agreement to raise approximately $10 million through a registered direct offering of common stock and pre-funded warrants.

Akoustis has finalized design updates to its XBAW manufacturing process to avoid patent infringement and announced a $10 million registered direct offering.

Akoustis Technologies has been found liable for trade secret misappropriation and patent infringement, resulting in a $38.6 million judgment against them, casting doubt on their financial future.

Akoustis Technologies reported a 7% quarter-over-quarter revenue increase in Q3 FY24, driven by a 13% rise in filter-related revenue, and anticipates operating cash flow breakeven within nine months.

Akoustis Technologies reported a 20% year-over-year revenue increase in the second fiscal quarter and anticipates record revenue in the upcoming March quarter.

Akoustis Technologies successfully completed a public offering of common stock, raising approximately $10.4 million to fund operations and growth.

Akoustis Technologies has released preliminary financial results for the second quarter of fiscal year 2024 and announced a proposed public offering of common stock.